Huimei Capital

Sniper develops accurate and intelligent molecular diagnostic solutions. Taking the next-generation fully automatic digital PCR as a breakthrough, the company has developed a droplet generation method with global independent intellectual property rights - Vibrant Injection technology and created a new path of chip-free droplet generation technology. It solves the pain points of high cost and complicated operation of microfluidic technology in practical application and is expected to bring subversive innovation in the field of refined medical testing.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company’s therapeutics are designed to significantly reduce the mortality, morbidity, and healthcare costs associated with these infections. Osteal Therapeutics offers solutions for orthopedic infections and infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for patients suffering from musculoskeletal diseases, ultimately improving patient outcomes and the overall management of these conditions.

Xushui Internet provides image equipment monitoring, operation, and maintenance cloud services, large-scale equipment IoT management system, digital integration services for hospital-wide equipment, and remote collaborative image inspection system.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company’s therapeutics are designed to significantly reduce the mortality, morbidity, and healthcare costs associated with these infections. Osteal Therapeutics offers solutions for orthopedic infections and infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for patients suffering from musculoskeletal diseases, ultimately improving patient outcomes and the overall management of these conditions.

SensView is a company focused on the development and production of solid-state imaging chips and detector modules. Its primary offerings include CMOS flat panel detectors and a range of X-ray detectors, such as computed tomography detectors and photon counting detectors. SensView utilizes advanced monocrystalline silicon technology to create these imaging solutions, which are designed to support various industrial applications. Through its innovative products, SensView aims to enhance imaging capabilities across multiple sectors.

Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating the effectiveness of protein design.

Bio-Engine is a company based in Shanghai, China, focused on the research and development of veterinary biological products. Founded in 2014, Bio-Engine specializes in creating and producing antibodies, recombinant proteins, and vaccines for both humans and livestock using serum-free suspension culture technology for animal cells. The company's expertise extends to providing clinical trial services for pharmaceutical manufacturers and scientific research units.

Coherent Biopharma is a pharmaceutical company focused on developing innovative drug therapies for oncology and chronic diseases. The company specializes in bi-targeting drug development technology, utilizing its proprietary platforms, including the BEST™ Platform, C-PROTAC Platform, and Chronic Diseases Platform. These technologies enable the creation of drugs that target specific tissues or organ sites, enhancing the effectiveness of treatments for various chronic conditions. By advancing its bi-targeting drug conjugation technology, Coherent Biopharma aims to improve patient outcomes through more precise and effective therapeutic options.

Xinrui Medical is a domestic enterprise that engages in the research and development of polymer valves. It focuses on new polymer valves to build a complete solution for heart valve disease. The team members have long been engaged in the research and development of polymer synthesis and polymer-related medical devices. They are all from well-known medical device companies and have complete product development experience and mature industrialization thinking.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Ruitai Biotechnology offers research, development, production, and sales of regenerative repair materials and related medical device products. They provide relevant technical services for other start-up biomedical companies to help them realize the transformation of scientific and technological achievements.

LePure Biotech, established in 2011 and headquartered in Shanghai, China, operates within the biotechnology and pharmaceutical sectors. The company specializes in the development and manufacturing of disposable biopharmaceutical process equipment and consumables, primarily focusing on products that facilitate the storage, transportation, filling, and leak detection of samples related to biosimilars, vaccines, and other biopharmaceutical applications. Its core offering is a disposable storage bag designed to meet the specific needs of these processes. Recently, LePure Biotech completed a B+ round of financing, which aims to fund the development of innovative products, establish a research and development center in the United States, enhance supply chain integration, and expand its R&D operations both domestically and internationally.

Sunpower Group is an enterprise driven by green investment, based and supported by manufacturing and engineering services, and driven by R&D and innovation. Sunpower Group is headquartered in Nanjing, Jiangning.

Jinjiang Electronic Technology is a med-tech company focused on the research and development as well as the manufacture of advanced medical equipment designed to enhance patient care in the field of cardiac electrophysiology. The company offers a range of innovative products, including a 3D cardiac mapping system, electrophysiology recording system, cardiac RF ablation generator, and irrigation pump. These devices provide comprehensive solutions aimed at diagnosing and treating arrhythmias, ultimately improving the quality of life for patients with heart conditions.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To address clients' therapeutic product demands at the pre-clinical, clinical, and commercial stages, the firm offers end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Coherent Biopharma is a pharmaceutical company focused on developing innovative drug therapies for oncology and chronic diseases. The company specializes in bi-targeting drug development technology, utilizing its proprietary platforms, including the BEST™ Platform, C-PROTAC Platform, and Chronic Diseases Platform. These technologies enable the creation of drugs that target specific tissues or organ sites, enhancing the effectiveness of treatments for various chronic conditions. By advancing its bi-targeting drug conjugation technology, Coherent Biopharma aims to improve patient outcomes through more precise and effective therapeutic options.

Ruitai Biotechnology offers research, development, production, and sales of regenerative repair materials and related medical device products. They provide relevant technical services for other start-up biomedical companies to help them realize the transformation of scientific and technological achievements.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

Gokin Solar specializes in the research and development, as well as the manufacturing, of high-efficiency large-size photovoltaic silicon wafers and monocrystalline silicon rods. Its product range includes 182mm and 210mm monocrystalline silicon rods and wafers, which are essential components in photovoltaic systems. These products are primarily utilized in large ground-based centralized power plants, as well as in industrial, commercial, and residential photovoltaic applications. By providing high-performance and high-quality silicon wafers, Gokin Solar supports enterprises within the photovoltaic industry in enhancing their energy solutions.

SensView is a company focused on the development and production of solid-state imaging chips and detector modules. Its primary offerings include CMOS flat panel detectors and a range of X-ray detectors, such as computed tomography detectors and photon counting detectors. SensView utilizes advanced monocrystalline silicon technology to create these imaging solutions, which are designed to support various industrial applications. Through its innovative products, SensView aims to enhance imaging capabilities across multiple sectors.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company’s therapeutics are designed to significantly reduce the mortality, morbidity, and healthcare costs associated with these infections. Osteal Therapeutics offers solutions for orthopedic infections and infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for patients suffering from musculoskeletal diseases, ultimately improving patient outcomes and the overall management of these conditions.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Quanrong Pharmaceutical has a nationally leading expert team in software engineering, information security, and product design. The product developed by the company is currently the leading clinical trial management system in the country, with a large number of independent intellectual property rights and extensive support from the clinical trial community. Through strategic cooperation, the company will jointly develop products suitable for global clinical trial informatization with strategic partners in North America and Europe within a few years, and will become the world's leading clinical trial informatization company.

Deyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology.

Yingmai Medical offers solutions for valve intervention, aortic and peripheral intervention, and neuromodulation. They are covering multiple innovative technology fields, such as structural heart disease treatment, pan-vascular disease treatment, nerve stimulation, and a brain-computer interface platform.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing innovative therapeutics for oncology and infectious diseases, with a particular emphasis on targeting dysfunctional lipid metabolism pathways. The company has a strong focus on fatty acid synthase (FASN) biology and has developed a pipeline of proprietary FASN inhibitors. Its lead product candidate, denifanstat, is an oral selective FASN inhibitor being investigated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, Sagimet is exploring antiviral therapeutic candidates aimed at treating respiratory syncytial virus, cytomegalovirus, and other human pathogens. Founded in 2006, Sagimet Biosciences was previously known as 3-V Biosciences, Inc. before rebranding in August 2019.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for cancer and autoimmune diseases. Founded in 2000 and headquartered in Rockville, Maryland, the company has a diverse development portfolio that includes CD24Fc, a recombinant fusion protein designed for the prophylactic treatment of acute graft versus host disease, particularly in leukemia patients undergoing hematopoietic stem cell transplantation. Additionally, OncoImmune is developing sialidase inhibitors as a therapeutic strategy to prevent sepsis, ONC-392, a monoclonal antibody that aims to reduce immune-related toxicities while maintaining effective anti-tumor responses, and Echinomycin, a cyclic peptide formulation targeting acute myeloid leukemia. The company has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication.

HuidaGene Therapeutics Co., Ltd., established in 2018, is a Shanghai-based biotechnology company specializing in the research and development of gene therapies for single-gene disorders and neurodegenerative diseases. The company employs its proprietary CRISPR-based, AI-driven HG-PRECISE platform to create potentially curative treatments. HuidaGene's clinical pipeline includes therapies for RPE65-associated retinal disease (HG004), neovascular age-related macular degeneration (nAMD) (HG202), MECP2 duplication syndrome (HG204), and Duchenne muscular dystrophy (DMD) (HG302). Additionally, the company has preclinical programs focused on therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

100doc is a Beijing-based live streaming video platform dedicated to enhancing medical knowledge and communication among healthcare professionals in China. The platform offers an interactive environment for online meetings, lectures, and training specifically for doctors. Additionally, it features a cloud-based software-as-a-service (SaaS) solution that enables medical institutions to record, store, manage, and share medical records, procedural operation recordings, and educational content. By facilitating the efficient exchange of information, 100doc aims to support the dissemination of leading medical knowledge and foster collaboration within the medical community across China.

Huimei Technology specializes in developing and designing artificial intelligence solutions aimed at enhancing clinical quality in healthcare. The company’s core offerings include a single disease process quality management system and a Clinical Decision Support System (CDSS) that integrates an evidence-based medical knowledge base. Utilizing advanced techniques such as natural language processing and deep learning, Huimei Technology processes clinical big data to provide real-time decision-making assistance for healthcare professionals. This integration of standard electronic clinical pathways and workflows allows clinicians to deliver more personalized and effective diagnoses and treatment plans based on individual patient conditions. The company's products are primarily targeted for use in outpatient, emergency, and inpatient settings within large hospitals, ultimately aiming to improve patient outcomes and the overall efficiency of medical services.